1 Spinal Muscular Atrophy Medicine Market Overview 1.1 Spinal Muscular Atrophy Medicine Product Overview 1.2 Spinal Muscular Atrophy Medicine Market Segment by Type 1.2.1 LMI-070 1.2.2 ND-602 1.2.3 NT-1654 1.2.4 Nusinersen 1.2.5 NXD-30001 1.2.6 Others 1.3 Global Spinal Muscular Atrophy Medicine Market Size by Type 1.3.1 Global Spinal Muscular Atrophy Medicine Market Size Overview by Type (2016-2027) 1.3.2 Global Spinal Muscular Atrophy Medicine Historic Market Size Review by Type (2016-2021) 1.3.2.1 Global Spinal Muscular Atrophy Medicine Sales Breakdown in Volume by Type (2016-2021) 1.3.2.2 Global Spinal Muscular Atrophy Medicine Sales Breakdown in Value by Type (2016-2021) 1.3.2.3 Global Spinal Muscular Atrophy Medicine Average Selling Price (ASP) by Type (2016-2021) 1.3.3 Global Spinal Muscular Atrophy Medicine Forecasted Market Size by Type (2022-2027) 1.3.3.1 Global Spinal Muscular Atrophy Medicine Sales Breakdown in Volume by Type (2022-2027) 1.3.3.2 Global Spinal Muscular Atrophy Medicine Sales Breakdown in Value by Type (2022-2027) 1.3.3.3 Global Spinal Muscular Atrophy Medicine Average Selling Price (ASP) by Type (2022-2027) 1.4 Key Regions Market Size Segment by Type 1.4.1 North America Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2016-2021) 1.4.2 Europe Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2016-2021) 1.4.3 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2016-2021) 1.4.4 Latin America Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2016-2021) 1.4.5 Middle East and Africa Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2016-2021) 2 Global Spinal Muscular Atrophy Medicine Market Competition by Company 2.1 Global Top Players by Spinal Muscular Atrophy Medicine Sales (2016-2021) 2.2 Global Top Players by Spinal Muscular Atrophy Medicine Revenue (2016-2021) 2.3 Global Top Players Spinal Muscular Atrophy Medicine Price (2016-2021) 2.4 Global Top Manufacturers Spinal Muscular Atrophy Medicine Manufacturing Base Distribution, Sales Area, Product Type 2.5 Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends 2.5.1 Spinal Muscular Atrophy Medicine Market Concentration Rate (2016-2021) 2.5.2 Global 5 and 10 Largest Manufacturers by Spinal Muscular Atrophy Medicine Sales and Revenue in 2020 2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2020) 2.7 Date of Key Manufacturers Enter into Spinal Muscular Atrophy Medicine Market 2.8 Key Manufacturers Spinal Muscular Atrophy Medicine Product Offered 2.9 Mergers & Acquisitions, Expansion 3 Spinal Muscular Atrophy Medicine Status and Outlook by Region 3.1 Global Spinal Muscular Atrophy Medicine Market Size and CAGR by Region: 2016 VS 2021 VS 2026 3.2 Global Spinal Muscular Atrophy Medicine Historic Market Size by Region 3.2.1 Global Spinal Muscular Atrophy Medicine Sales in Volume by Region (2016-2021) 3.2.2 Global Spinal Muscular Atrophy Medicine Sales in Value by Region (2016-2021) 3.2.3 Global Spinal Muscular Atrophy Medicine Sales (Volume & Value) Price and Gross Margin (2016-2021) 3.3 Global Spinal Muscular Atrophy Medicine Forecasted Market Size by Region 3.3.1 Global Spinal Muscular Atrophy Medicine Sales in Volume by Region (2022-2027) 3.3.2 Global Spinal Muscular Atrophy Medicine Sales in Value by Region (2022-2027) 3.3.3 Global Spinal Muscular Atrophy Medicine Sales (Volume & Value), Price and Gross Margin (2022-2027) 4 Global Spinal Muscular Atrophy Medicine by Application 4.1 Spinal Muscular Atrophy Medicine Market Segment by Application 4.1.1 Hospital 4.1.2 Clinic 4.1.3 Others 4.2 Global Spinal Muscular Atrophy Medicine Market Size by Application 4.2.1 Global Spinal Muscular Atrophy Medicine Market Size Overview by Application (2016-2027) 4.2.2 Global Spinal Muscular Atrophy Medicine Historic Market Size Review by Application (2016-2021) 4.2.2.1 Global Spinal Muscular Atrophy Medicine Sales Breakdown in Volume, by Application (2016-2021) 4.2.2.2 Global Spinal Muscular Atrophy Medicine Sales Breakdown in Value, by Application (2016-2021) 4.2.2.3 Global Spinal Muscular Atrophy Medicine Average Selling Price (ASP) by Application (2016-2021) 4.2.3 Global Spinal Muscular Atrophy Medicine Forecasted Market Size by Application (2022-2027) 4.2.3.1 Global Spinal Muscular Atrophy Medicine Sales Breakdown in Volume, by Application (2022-2027) 4.2.3.2 Global Spinal Muscular Atrophy Medicine Sales Breakdown in Value, by Application (2022-2027) 4.2.3.3 Global Spinal Muscular Atrophy Medicine Average Selling Price (ASP) by Application (2022-2027) 4.3 Key Regions Market Size Segment by Application 4.3.1 North America Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2016-2021) 4.3.2 Europe Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2016-2021) 4.3.3 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2016-2021) 4.3.4 Latin America Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2016-2021) 4.3.5 Middle East and Africa Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2016-2021) 5 North America Spinal Muscular Atrophy Medicine by Country 5.1 North America Spinal Muscular Atrophy Medicine Historic Market Size by Country 5.1.1 North America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2016-2021) 5.1.2 North America Spinal Muscular Atrophy Medicine Sales in Value by Country (2016-2021) 5.2 North America Spinal Muscular Atrophy Medicine Forecasted Market Size by Country 5.2.1 North America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2022-2027) 5.2.2 North America Spinal Muscular Atrophy Medicine Sales in Value by Country (2022-2027) 6 Europe Spinal Muscular Atrophy Medicine by Country 6.1 Europe Spinal Muscular Atrophy Medicine Historic Market Size by Country 6.1.1 Europe Spinal Muscular Atrophy Medicine Sales in Volume by Country (2016-2021) 6.1.2 Europe Spinal Muscular Atrophy Medicine Sales in Value by Country (2016-2021) 6.2 Europe Spinal Muscular Atrophy Medicine Forecasted Market Size by Country 6.2.1 Europe Spinal Muscular Atrophy Medicine Sales in Volume by Country (2022-2027) 6.2.2 Europe Spinal Muscular Atrophy Medicine Sales in Value by Country (2022-2027) 7 Asia-Pacific Spinal Muscular Atrophy Medicine by Region 7.1 Asia-Pacific Spinal Muscular Atrophy Medicine Historic Market Size by Region 7.1.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Volume by Region (2016-2021) 7.1.2 Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Value by Region (2016-2021) 7.2 Asia-Pacific Spinal Muscular Atrophy Medicine Forecasted Market Size by Region 7.2.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Volume by Region (2022-2027) 7.2.2 Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Value by Region (2022-2027) 8 Latin America Spinal Muscular Atrophy Medicine by Country 8.1 Latin America Spinal Muscular Atrophy Medicine Historic Market Size by Country 8.1.1 Latin America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2016-2021) 8.1.2 Latin America Spinal Muscular Atrophy Medicine Sales in Value by Country (2016-2021) 8.2 Latin America Spinal Muscular Atrophy Medicine Forecasted Market Size by Country 8.2.1 Latin America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2022-2027) 8.2.2 Latin America Spinal Muscular Atrophy Medicine Sales in Value by Country (2022-2027) 9 Middle East and Africa Spinal Muscular Atrophy Medicine by Country 9.1 Middle East and Africa Spinal Muscular Atrophy Medicine Historic Market Size by Country 9.1.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Volume by Country (2016-2021) 9.1.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Value by Country (2016-2021) 9.2 Middle East and Africa Spinal Muscular Atrophy Medicine Forecasted Market Size by Country 9.2.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Volume by Country (2022-2027) 9.2.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Value by Country (2022-2027) 10 Company Profiles and Key Figures in Spinal Muscular Atrophy Medicine Business 10.1 Astellas Pharma Inc. 10.1.1 Astellas Pharma Inc. Corporation Information 10.1.2 Astellas Pharma Inc. Introduction and Business Overview 10.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Products Offered 10.1.5 Astellas Pharma Inc. Recent Development 10.2 AveXis, Inc. 10.2.1 AveXis, Inc. Corporation Information 10.2.2 AveXis, Inc. Introduction and Business Overview 10.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.2.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Products Offered 10.2.5 AveXis, Inc. Recent Development 10.3 Bioblast Pharma Ltd. 10.3.1 Bioblast Pharma Ltd. Corporation Information 10.3.2 Bioblast Pharma Ltd. Introduction and Business Overview 10.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Products Offered 10.3.5 Bioblast Pharma Ltd. Recent Development 10.4 Cytokinetics, Inc. 24 10.4.1 Cytokinetics, Inc. 24 Corporation Information 10.4.2 Cytokinetics, Inc. 24 Introduction and Business Overview 10.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Products Offered 10.4.5 Cytokinetics, Inc. 24 Recent Development 10.5 F. Hoffmann-La Roche Ltd. 10.5.1 F. Hoffmann-La Roche Ltd. Corporation Information 10.5.2 F. Hoffmann-La Roche Ltd. Introduction and Business Overview 10.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Products Offered 10.5.5 F. Hoffmann-La Roche Ltd. Recent Development 10.6 Genethon 10.6.1 Genethon Corporation Information 10.6.2 Genethon Introduction and Business Overview 10.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.6.4 Genethon Spinal Muscular Atrophy Medicine Products Offered 10.6.5 Genethon Recent Development 10.7 Genzyme Corporation 10.7.1 Genzyme Corporation Corporation Information 10.7.2 Genzyme Corporation Introduction and Business Overview 10.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Products Offered 10.7.5 Genzyme Corporation Recent Development 10.8 GMP-Orphan SAS 10.8.1 GMP-Orphan SAS Corporation Information 10.8.2 GMP-Orphan SAS Introduction and Business Overview 10.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Products Offered 10.8.5 GMP-Orphan SAS Recent Development 10.9 Ionis Pharmaceuticals, Inc. 10.9.1 Ionis Pharmaceuticals, Inc. Corporation Information 10.9.2 Ionis Pharmaceuticals, Inc. Introduction and Business Overview 10.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Products Offered 10.9.5 Ionis Pharmaceuticals, Inc. Recent Development 10.10 Longevity Biotech, Inc 10.10.1 Company Basic Information, Manufacturing Base and Competitors 10.10.2 Spinal Muscular Atrophy Medicine Product Category, Application and Specification 10.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2016-2021) 10.10.4 Main Business Overview 10.10.5 Longevity Biotech, Inc Recent Development 10.11 Neurodyn Inc. 10.11.1 Neurodyn Inc. Corporation Information 10.11.2 Neurodyn Inc. Introduction and Business Overview 10.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Products Offered 10.11.5 Neurodyn Inc. Recent Development 10.12 Neurotune AG 10.12.1 Neurotune AG Corporation Information 10.12.2 Neurotune AG Introduction and Business Overview 10.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.12.4 Neurotune AG Spinal Muscular Atrophy Medicine Products Offered 10.12.5 Neurotune AG Recent Development 10.13 Novartis AG 10.13.1 Novartis AG Corporation Information 10.13.2 Novartis AG Introduction and Business Overview 10.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.13.4 Novartis AG Spinal Muscular Atrophy Medicine Products Offered 10.13.5 Novartis AG Recent Development 10.14 Sarepta Therapeutics, Inc. 10.14.1 Sarepta Therapeutics, Inc. Corporation Information 10.14.2 Sarepta Therapeutics, Inc. Introduction and Business Overview 10.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.14.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Products Offered 10.14.5 Sarepta Therapeutics, Inc. Recent Development 10.15 Voyager Therapeutics, Inc. 10.15.1 Voyager Therapeutics, Inc. Corporation Information 10.15.2 Voyager Therapeutics, Inc. Introduction and Business Overview 10.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.15.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Products Offered 10.15.5 Voyager Therapeutics, Inc. Recent Development 10.16 Vybion, Inc. 10.16.1 Vybion, Inc. Corporation Information 10.16.2 Vybion, Inc. Introduction and Business Overview 10.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.16.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Products Offered 10.16.5 Vybion, Inc. Recent Development 10.17 WAVE Life Sciences Ltd. 10.17.1 WAVE Life Sciences Ltd. Corporation Information 10.17.2 WAVE Life Sciences Ltd. Introduction and Business Overview 10.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 10.17.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Products Offered 10.17.5 WAVE Life Sciences Ltd. Recent Development 11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis 11.1 Spinal Muscular Atrophy Medicine Key Raw Materials 11.1.1 Key Raw Materials 11.1.2 Key Raw Materials Price 11.1.3 Raw Materials Key Suppliers 11.2 Manufacturing Cost Structure 11.2.1 Raw Materials 11.2.2 Labor Cost 11.2.3 Manufacturing Expenses 11.3 Spinal Muscular Atrophy Medicine Industrial Chain Analysis 11.4 Spinal Muscular Atrophy Medicine Market Dynamics 11.4.1 Industry Trends 11.4.2 Market Drivers 11.4.3 Market Challenges 11.4.4 Market Restraints 12 Market Strategy Analysis, Distributors 12.1 Sales Channel 12.2 Spinal Muscular Atrophy Medicine Distributors 12.3 Spinal Muscular Atrophy Medicine Downstream Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.1.1 Research Programs/Design 14.1.1.2 Market Size Estimation 14.1.1.3 Market Breakdown and Data Triangulation 14.1.2 Data Source 14.1.2.1 Secondary Sources 14.1.2.2 Primary Sources 14.2 Author Details 14.3 Disclaimer

List of Tables Table 1. Major Company of LMI-070 Table 2. Major Company of ND-602 Table 3. Major Company of NT-1654 Table 4. Major Company of Nusinersen Table 5. Major Company of NXD-30001 Table 6. Major Company of Others Table 7. Global Spinal Muscular Atrophy Medicine Sales by Type 2016 VS 2021 VS 2027 (US$ Million) Table 8. Global Spinal Muscular Atrophy Medicine Sales by Type (2016-2021) & (K Pcs) Table 9. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2016-2021) Table 10. Global Spinal Muscular Atrophy Medicine Sales by Type (2016-2021) & (US& Million) Table 11. Global Spinal Muscular Atrophy Medicine Market Share in Value by Type (2016-2021) Table 12. Global Spinal Muscular Atrophy Medicine Price by Type (2016-2021) & (USD/Pcs) Table 13. Global Spinal Muscular Atrophy Medicine Sales by Type (2022-2027) & (K Pcs) Table 14. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2022-2027) Table 15. Global Spinal Muscular Atrophy Medicine Sales by Type (2022-2027) & (US$ Million) Table 16. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type (2022-2027) Table 17. Global Spinal Muscular Atrophy Medicine Price by Type (2022-2027) & (USD/Pcs) Table 18. North America Spinal Muscular Atrophy Medicine Sales by Type (2016-2021) & (K Pcs) Table 19. North America Spinal Muscular Atrophy Medicine Sales by Type (2016-2021) & (US$ Million) Table 20. Europe Spinal Muscular Atrophy Medicine Sales (K Pcs) by Type (2016-2021) Table 21. Europe Spinal Muscular Atrophy Medicine Sales by Type (2016-2021) & (US$ Million) Table 22. Asia-Pacific Spinal Muscular Atrophy Medicine Sales (K Pcs) by Type (2016-2021) Table 23. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Type (2016-2021) & (US$ Million) Table 24. Latin America Spinal Muscular Atrophy Medicine Sales (K Pcs) by Type (2016-2021) Table 25. Latin America Spinal Muscular Atrophy Medicine Sales by Type (2016-2021) & (US$ Million) Table 26. Middle East and Africa Spinal Muscular Atrophy Medicine Sales (K Pcs) by Type (2016-2021) Table 27. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Type (2016-2021) & (US$ Million) Table 28. Global Spinal Muscular Atrophy Medicine Sales by Company (2016-2021) & (K Pcs) Table 29. Global Spinal Muscular Atrophy Medicine Sales Share by Company (2016-2021) Table 30. Global Spinal Muscular Atrophy Medicine Revenue by Company (2016-2021) & (US$ Million) Table 31. Global Spinal Muscular Atrophy Medicine Revenue Share by Company (2016-2021) Table 32. Global Market Spinal Muscular Atrophy Medicine Price by Company (2016-2021) & (USD/Pcs) Table 33. Global Spinal Muscular Atrophy Medicine Top Manufacturers Manufacturing Base Distribution and Sales Area Table 34. Global Spinal Muscular Atrophy Medicine Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2020 Table 36. Date of Key Manufacturers Enter into Spinal Muscular Atrophy Medicine Market Table 37. Key Manufacturers Spinal Muscular Atrophy Medicine Product Type Table 38. Mergers & Acquisitions, Expansion Plans Table 39. Global Spinal Muscular Atrophy Medicine Market Size Comparison by Region (US$ Million): 2016 VS 2021 VS 2027 Table 40. Global Spinal Muscular Atrophy Medicine Sales by Region (2016-2021) & (K Pcs) Table 41. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Region (2016-2021) Table 42. Global Spinal Muscular Atrophy Medicine Sales by Region (2016-2021) & (US$ Million) Table 43. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Region (2016-2021) Table 44. Global Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 45. Global Spinal Muscular Atrophy Medicine Sales by Region (2022-2027) & (K Pcs) Table 46. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Region (2022-2027) Table 47. Global Spinal Muscular Atrophy Medicine Sales by Region (2022-2027) & (US$ Million) Table 48. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Region (2022-2027) Table 49. Global Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2022-2027) Table 50. Global Spinal Muscular Atrophy Medicine Sales by Application: 2016 VS 2021 VS 2027 (US$ Million) Table 51. Global Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) & (K Pcs) Table 52. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2016-2021) Table 53. Global Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) & (US$ Million) Table 54. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application (2016-2021) Table 55. Global Spinal Muscular Atrophy Medicine Price by Application (2016-2021) & (USD/Pcs) Table 56. Global Spinal Muscular Atrophy Medicine Sales by Application (2022-2027) & (K Pcs) Table 57. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2022-2027) Table 58. Global Spinal Muscular Atrophy Medicine Sales by Application (2022-2027) & (US$ Million) Table 59. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application (2022-2027) Table 60. Global Spinal Muscular Atrophy Medicine Price by Application (2022-2027) & (USD/Pcs) Table 61. North America Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) (K Pcs) Table 62. North America Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) & (US$ Million) Table 63. North America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2020 Table 64. Europe Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) (K Pcs) Table 65. Europe Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) & (US$ Million) Table 66. Europe Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2020 Table 67. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) (K Pcs) Table 68. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) & (US$ Million) Table 69. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2020 Table 70. Latin America Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) (K Pcs) Table 71. Latin America Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) & (US$ Million) Table 72. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2020 Table 73. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) (K Pcs) Table 74. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Application (2016-2021) & (US$ Million) Table 75. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2020 Table 76. North America Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (K Pcs) Table 77. North America Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Country (2016-2021) Table 78. North America Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (US$ Million) Table 79. North America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Country (2016-2021) Table 80. North America Spinal Muscular Atrophy Medicine Sales by Country (2022-2027) & (K Pcs) Table 81. North America Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Country (2022-2027) Table 82. North America Spinal Muscular Atrophy Medicine Sales by Country (2022-2027) & (US$ Million) Table 83. North America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Country (2022-2027) Table 84. Europe Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (K Pcs) Table 85. Europe Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Country (2016-2021) Table 86. Europe Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (US$ Million) Table 87. Europe Spinal Muscular Atrophy Medicine Sales Market Share in Value by Country (2016-2021) Table 88. Europe Spinal Muscular Atrophy Medicine Sales by Country (2022-2027) & (K Pcs) Table 89. Europe Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Country (2022-2027) Table 90. Europe Spinal Muscular Atrophy Medicine Sales by Country (2022-2027) & (US$ Million) Table 91. Europe Spinal Muscular Atrophy Medicine Sales Market Share in Value by Country (2022-2027) Table 92. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Region (2016-2021) & (K Pcs) Table 93. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Region (2016-2021) Table 94. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Region (2016-2021) & (US$ Million) Table 95. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share in Value by Region (2016-2021) Table 96. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Region (2022-2027) & (K Pcs) Table 97. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Region (2022-2027) Table 98. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Region (2022-2027) & (US$ Million) Table 99. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share in Value by Region (2022-2027) Table 100. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (K Pcs) Table 101. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Country (2016-2021) Table 102. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (US$ Million) Table 103. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Country (2016-2021) Table 104. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2022-2027) & (K Pcs) Table 105. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Country (2022-2027) Table 106. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2022-2027) & (US$ Million) Table 107. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Country (2022-2027) Table 108. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (K Pcs) Table 109. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Country (2016-2021) Table 110. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (US$ Million) Table 111. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Value by Country (2016-2021) Table 112. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2022-2027) & (K Pcs) Table 113. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Country (2022-2027) Table 114. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2022-2027) & (US$ Million) Table 115. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Value by Country (2022-2027) Table 116. Astellas Pharma Inc. Corporation Information Table 117. Astellas Pharma Inc. Introduction and Business Overview Table 118. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 119. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Table 120. Astellas Pharma Inc. Recent Development Table 121. AveXis, Inc. Corporation Information Table 122. AveXis, Inc. Introduction and Business Overview Table 123. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 124. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Table 125. AveXis, Inc. Recent Development Table 126. Bioblast Pharma Ltd. Corporation Information Table 127. Bioblast Pharma Ltd. Introduction and Business Overview Table 128. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 129. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Table 130. Bioblast Pharma Ltd. Recent Development Table 131. Cytokinetics, Inc. 24 Corporation Information Table 132. Cytokinetics, Inc. 24 Introduction and Business Overview Table 133. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 134. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Table 135. Cytokinetics, Inc. 24 Recent Development Table 136. F. Hoffmann-La Roche Ltd. Corporation Information Table 137. F. Hoffmann-La Roche Ltd. Introduction and Business Overview Table 138. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 139. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Table 140. F. Hoffmann-La Roche Ltd. Recent Development Table 141. Genethon Corporation Information Table 142. Genethon Introduction and Business Overview Table 143. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 144. Genethon Spinal Muscular Atrophy Medicine Product Table 145. Genethon Recent Development Table 146. Genzyme Corporation Corporation Information Table 147. Genzyme Corporation Introduction and Business Overview Table 148. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 149. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Table 150. Genzyme Corporation Recent Development Table 151. GMP-Orphan SAS Corporation Information Table 152. GMP-Orphan SAS Introduction and Business Overview Table 153. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 154. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Table 155. GMP-Orphan SAS Recent Development Table 156. Ionis Pharmaceuticals, Inc. Corporation Information Table 157. Ionis Pharmaceuticals, Inc. Introduction and Business Overview Table 158. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 159. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Table 160. Ionis Pharmaceuticals, Inc. Recent Development Table 161. Longevity Biotech, Inc Corporation Information Table 162. Longevity Biotech, Inc Introduction and Business Overview Table 163. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 164. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Table 165. Longevity Biotech, Inc Recent Development Table 166. Neurodyn Inc. Corporation Information Table 167. Neurodyn Inc. Introduction and Business Overview Table 168. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 169. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Table 170. Neurodyn Inc. Recent Development Table 171. Neurotune AG Corporation Information Table 172. Neurotune AG Introduction and Business Overview Table 173. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 174. Neurotune AG Spinal Muscular Atrophy Medicine Product Table 175. Neurotune AG Recent Development Table 176. Novartis AG Corporation Information Table 177. Novartis AG Introduction and Business Overview Table 178. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 179. Novartis AG Spinal Muscular Atrophy Medicine Product Table 180. Novartis AG Recent Development Table 181. Sarepta Therapeutics, Inc. Corporation Information Table 182. Sarepta Therapeutics, Inc. Introduction and Business Overview Table 183. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 184. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Table 185. Sarepta Therapeutics, Inc. Recent Development Table 186. Voyager Therapeutics, Inc. Corporation Information Table 187. Voyager Therapeutics, Inc. Introduction and Business Overview Table 188. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 189. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Table 190. Voyager Therapeutics, Inc. Recent Development Table 191. Vybion, Inc. Corporation Information Table 192. Vybion, Inc. Introduction and Business Overview Table 193. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 194. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Table 195. Vybion, Inc. Recent Development Table 196. WAVE Life Sciences Ltd. Corporation Information Table 197. WAVE Life Sciences Ltd. Introduction and Business Overview Table 198. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 199. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Table 200. WAVE Life Sciences Ltd. Recent Development Table 201. Key Raw Materials Lists Table 202. Raw Materials Key Suppliers Lists Table 203. Spinal Muscular Atrophy Medicine Market Trends Table 204. Spinal Muscular Atrophy Medicine Market Drivers Table 205. Spinal Muscular Atrophy Medicine Market Challenges Table 206. Spinal Muscular Atrophy Medicine Market Restraints Table 207. Spinal Muscular Atrophy Medicine Distributors List Table 208. Spinal Muscular Atrophy Medicine Downstream Customers Table 209. Research Programs/Design for This Report Table 210. Key Data Information from Secondary Sources Table 211. Key Data Information from Primary Sources List of Figures Figure 1. Spinal Muscular Atrophy Medicine Product Picture Figure 2. Global Spinal Muscular Atrophy Medicine Market Size, 2016 VS 2021 VS 2027 (US$ Million) Figure 3. Global Spinal Muscular Atrophy Medicine Market Size Status and Outlook (2016-2027) & (US$ Million) Figure 4. Global Spinal Muscular Atrophy Medicine Sales Status and Outlook (2016-2027) & (K Pcs) Figure 5. Product Picture of LMI-070 Figure 6. Global LMI-070 Sales YoY Growth (2016-2021) & (K Pcs) Figure 7. Product Picture of ND-602 Figure 8. Global ND-602 Sales YoY Growth (2016-2021) & (K Pcs) Figure 9. Product Picture of NT-1654 Figure 10. Global NT-1654 Sales YoY Growth (2016-2021) & (K Pcs) Figure 11. Product Picture of Nusinersen Figure 12. Global Nusinersen Sales YoY Growth (2016-2021) & (K Pcs) Figure 13. Product Picture of NXD-30001 Figure 14. Global NXD-30001 Sales YoY Growth (2016-2021) & (K Pcs) Figure 15. Product Picture of Others Figure 16. Global Others Sales YoY Growth (2016-2021) & (K Pcs) Figure 17. Global Spinal Muscular Atrophy Medicine Sales by Type (2016-2027) & (US$ Million) Figure 18. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2016-2021) Figure 19. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type (2016-2021) Figure 20. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2022-2027) Figure 21. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type (2022-2027) Figure 22. North America Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type in 2020 Figure 23. North America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type in 2020 Figure 24. Europe Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type in 2020 Figure 25. Europe Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type in 2020 Figure 26. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type in 2020 Figure 27. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type in 2020 Figure 28. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type in 2020 Figure 29. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type in 2020 Figure 30. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type in 2020 Figure 31. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type in 2020 Figure 32. The 5 and 10 Largest Manufacturers in the World: Market Share by Spinal Muscular Atrophy Medicine Sales in 2020 Figure 33. The 5 and 10 Largest Manufacturers in the World: Market Share by Spinal Muscular Atrophy Medicine Revenue in 2020 Figure 34. Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020 Figure 35. Product Picture of Hospital Figure 36. Global Hospital Sales YoY Growth (2016-2027) & (K Pcs) Figure 37. Product Picture of Clinic Figure 38. Global Clinic Sales YoY Growth (2016-2027) & (K Pcs) Figure 39. Product Picture of Others Figure 40. Global Others Sales YoY Growth (2016-2027) & (K Pcs) Figure 41. Global Spinal Muscular Atrophy Medicine Sales by Application (2016-2027) & (US$ Million) Figure 42. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2016-2021) Figure 43. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application (2016-2021) Figure 44. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2022-2027) Figure 45. North America Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application in 2020 Figure 46. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2020 Figure 47. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2020 Figure 48. Key Raw Materials Price Figure 49. Spinal Muscular Atrophy Medicine Manufacturing Cost Structure Figure 50. Spinal Muscular Atrophy Medicine Industrial Chain Analysis Figure 51. Channels of Distribution Figure 52. Distributors Profiles Figure 53. Bottom-up and Top-down Approaches for This Report Figure 54. Data Triangulation Figure 55. Key Executives Interviewed

Astellas Pharma Inc. AveXis, Inc. Bioblast Pharma Ltd. Cytokinetics, Inc. 24 F. Hoffmann-La Roche Ltd. Genethon Genzyme Corporation GMP-Orphan SAS Ionis Pharmaceuticals, Inc. Longevity Biotech, Inc Neurodyn Inc. Neurotune AG Novartis AG Sarepta Therapeutics, Inc. Voyager Therapeutics, Inc. Vybion, Inc. WAVE Life Sciences Ltd.